| Date | Title | Description |
| 15.09.2026 | The Scientist Announces the 2026 Top Innovations Winners | Ten groundbreaking technologies are recognized across biotechnology, healthcare, lab tools, and startup innovations.
WILMINGTON, Del., Sept. 15, 2026 /PRNewswire-PRWeb/ -- The Scientist proudly unveils the winners of this year's Top Innovat... |
| 11.05.2026 | Nuclera launches antibody triage service to advance AI-driven antibody discovery | Rapid binder triage, of AI-driven candidate sets, enables early elimination of non-binders ahead of costly downstream workflows
Powered by cell-free technology to convert AI-generated candidates into experimental binding data
Cambridge, UK ... |
| 30.03.2026 | Nuclera launches GPCR-focused nanodisc panel to streamline membrane protein production | Enables expression of active GPCRs in 48 hours
Panel supports screening to scale-up on eProtein Discovery
Cambridge, UK, and Boston MA, USA, 30 March 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins, t... |
| 15.01.2026 | Nuclera Scoops Up $12M Series C Round |
BOSTON, MA, Nuclera has announced a $12 million financing extension, bringing the Company's total Series C funding to $87 million.
>> Click here for more funding data on Nuclera
>> To export Nuclera funding data to PDF and Exce... |
| 14.01.2026 | Nuclera Accelerates AI-Driven Antibody Engineering with $87 Million Capital Infusion | Nuclera secures an additional $12 million, elevating Series C funding to $87 million. This critical capital fuels accelerated antibody engineering on its eProtein Discovery benchtop system. The biotech leader targets AI-enabled protein deve... |
| 13.01.2026 | Nuclera extends Series C funding to $87M to advance antibody engineering | Additional $12M financing led by Elevage Medical Technologies and Jonathan Milner alongside existing investors British Business Bank, and GK Goh
The funding will accelerate development of eProtein Discovery for full-format antibody expressi... |
| 13.01.2026 | Nuclera extends Series C funding to $87M to accelerate antibody engineering work | Biotech company Nuclera has secured an additional $12 million in financing, bringing its total Series C funding to $87 million. The extension was led by Elevage Medical Technologies and Jonathan Milner, with participation from existing inve... |
| 13.01.2026 | Nuclera Extends Series C Funding To $87 Million To Advance Antibody Engineering | Nuclera, a biotech company developing a benchtop platform for rapid access to functional proteins, has raised a $12 million extension to its Series C financing, bringing total Series C funding to $87 million.
The extension was led by Elevag... |
| 13.01.2026 | UK’s Nuclera brings Series C funding to €74 million following €10 million extension for its eProtein Discovery system | Cambridge-based Nuclera, a BioTech company accelerating drug discovery by providing access to functional proteins through its benchtop eProtein Discovery System, today announced a €10 million ($12 million) financing extension, bringing the ... |
| 03.11.2025 | Nuclera expands access to eProtein Discovery for APAC customers with distributor agreement in Australia and New Zealand | Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion
Cambridge, UK, and Boston MA, USA, 03 November 2025: Nuclera, the biotechnology company accelerating drug discovery by providing rapid, ea... |
| 14.04.2025 | Nuclera expands eProtein Discovery capabilities to enable membrane protein production | Membrane proteins synthesized and purified within 48 hours.
Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized
Cambridge, UK, and Boston MA, USA, 14 April 2025: Nuclera, the biotechnology company accelerat... |
| 11.11.2024 | October 2024's top 10 European tech deals you need to know about | According to the Tech.eu database, European tech companies raised €4 billion over the course of October 2024. This figure is nearly the same as last month when European tech companies raised €4.2 billion in September. Compared to October 20... |
| 22.10.2024 | Nuclera: Biotech Company Raises $75 Million For Accelerating Protein Expression | Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, announced it had completed a $75 million financing round (circa £57 million). The funding round was led by El... |
| 18.10.2024 | Nuclera raises $75M, 20VC's 3rd Fund soars to $400M, and EU push for a single pan-European startup entity | This week we tracked more than 85 tech funding deals worth over €774 million, and over 15 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most i... |
| 17.10.2024 | Nuclera's $75 Million Leap: A New Era for Protein Discovery | In the world of biotechnology, speed is everything. Nuclera, a Cambridge-based biotech company, has just secured a $75 million Series C funding round. This significant investment is a game-changer, pushing the boundaries of protein discover... |
| 16.10.2024 | Nuclera Raises $75M in Financing | Nuclera, a Cambridge, UK-based biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, raised $75M in funding.
The round was led by Elevage Medical Technologies, backed by Patien... |
| 16.10.2024 | Nuclera closes $75 million USD financing | Series C round led by Elevage Medical Technologies. Funding will accelerate the commercialization of Nuclera’s eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally.
Series C ro... |
| 16.10.2024 | Nuclera raises $75M Series C for eProtein discovery system | Biotech Nuclera has raised a $75 million Series C financing round. This brings the company’s funding to over $140 million.
The company is accelerating protein expression and purification workflows through its benchtop protein system, eProte... |
| 28.09.2022 | Innovative 3D printing-enabled strain sensor unlocks real-time monitoring of cancerous tumors | Researchers at Stanford University have used 3D printing to develop a strain sensor that enables the wireless monitoring of tumor regression in cancer patients.
Composed of a 50-nm layer of gold, drop-casted onto a flexible polymer enclosed... |
| 14.07.2022 | Nuclera raises another $15.5M towards launch of gene protein 3D bioprinting technology | Biotechnology start-up Nuclera has attracted a further $15.5 million in Series B funding, taking its total raised in the round up to $58 million.
Much like the initial $42.5 million it raised earlier this year, Nuclera plans to use this add... |
| 03.02.2022 | Nuclera raises $42.5M in first close of Series B for desktop protein printer | Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, announces that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and co... |
| 03.02.2022 | Nuclera raises $42.5M in first close of Series B for desktop protein printer | Nuclera raises $42.5M in first close of Series B for desktop protein printer
03-02-2022
Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, announces that the first close of its Series B financing has ... |
| 02.02.2022 | UK biotech startup ropes in $42.5 million to create 3D protein printer | Biotech company developing cutting-edge benchtop protein printing technologies, Nuclera has raised $42.5 million funding in Series B. The round saw the participation of new and existing institutional and strategic investors, including M&... |
| 02.02.2022 | Nuclera raises $42.5M towards launch of new protein 3D printer that “makes drug discovery accessible” | Insiders and analysts have made their predictions on the 3D printing trends to watch out for. Find out more in our series focused on the future of 3D printing.
Biotechnology start-up Nuclera has raised $42.5 million towards the launch of a ... |
| 02.02.2022 | Nuclera Raises $42.5M in First Close of Series B Financing | Nuclera, a Cambridge, UK- and Boston, Massachusetts-based biotech company developing benchtop protein printing technologies, raised $42.5 million in the first close of its Series B financing.
Backers included M&G, Amadeus Capital Partne... |
| 02.02.2022 | M&G : invests $10 million into Nuclera as it expands its technology range for research and drug discovery | News release
M&G invests $10 million into Nuclera as it expands its technology range for
research and drug discovery
London, 2 February 2022 - M&G announces it has become the latest investor into Nuclera Nucleics Ltd ("Nuclera&... |
| 23.05.2020 | Mike Kamdar, The Future Of DNA Writing, And The Business Of Biology | With a new way to write DNA, Mike Kamdar and his team at Molecular Assemblies are poised to disrupt just about any industry you can imagine. |
| - | Nuclera | “Rapid protein prototyping, making proteins accessible — it’s what we do. It’s what we deliver. Click here to learn more.” |
| - | Cambridge-based Nuclera is making biology accessible via desktop bioprinting, wraps up Series B at $58 million | Cambridge-headquartered biotechnology company accelerating protein expression workflows, Nuclera has raised an additional $15.5 million in Series B financing to bring the total to $58 million.
The investment, backed by Jonathan Milner and V... |
| - | UK biotech startup ropes in $42.5 million to create 3D protein printer | Biotech company developing cutting-edge benchtop protein printing technologies, Nuclera has raised $42.5 million funding in Series B. The round saw the participation of new and existing institutional and strategic investors, including M&... |
